Skip to : [Content] [Navigation]
Medical Product Manufacturing News
 

Archive for January, 2009

Peptides vs. Superbug: The Ultimate Showdown?

Friday, January 30th, 2009
Image Credit: University of British Columbia

Image Credit: University of British Columbia

High rates of infection stemming from surgical implantation are causing device manufacturers to scramble for bacteria-fighting coatings and additives to incorporate in their products. Researchers at the University of British Columbia (UBC; Vancouver) have discovered that synthetic-form, short, tethered, cationic antimicrobial peptides have demonstrated efficacy at killing bacteria that come into contact with them.

Naturally occurring peptides, or ‘nature’s antibiotics,’ combat bacteria in humans and animals and are located in various cells and tissues. Mimicking these proteins, the researchers created the cationic peptides as soluble antibiotics for use in coating implants. The distinguishing characteristic of these peptides is that they are active when tethered to a surface, whereas some peptides that are successful antibiotics in solution are not effective when applied to a substrate, according to Robert Hancock, principal investigator and Canada Research chair in pathogenomics and antimicrobials at the UBC Department of Microbiology and Immunology.

In recent years, the rise of the antibiotic-resistant ‘Superbug’ has made treatment of implant-associated infections increasingly difficult. The UBC researchers believe that applying short-tethered cationic antimicrobial peptides to implant surfaces could provide a nonantibiotic solution to inhibiting bacterial growth on devices.

An in-depth explanation of the research appears in the January 30 issue of Chemistry and Biology.

Methods Machine Tools Turns 50

Friday, January 30th, 2009

In 2009, Methods Machine Tools (Sudbury, MA) will be celebrating its 50th anniversary. Since its humble beginnings in 1958 as a three-person operation equipped with only a few refurbished machines, the company has swelled to employ more than 300 people, expanded to include seven facilities and technology centers, and installed more than 27,000 systems. Among the company’s offerings are EDM machines, five-axis machining centers, multitasking CNC lathes, and robotics.

Throughout this year, Methods Machine Tools will be marking this milestone at various industry events and through various promotions. The celebration will culminate in a three-day Methods Milestone open house event from September 15–17.

EaglePicher Medical Power Moves to Texas

Thursday, January 29th, 2009
EaglePicher Medical Power supplies batteries for implantable medical devices, such as its Micro Cell battery, which can be deployed via a minimally invasive catheter.

EaglePicher Medical Power supplies batteries for implantable medical devices, such as its Micro Cell battery, which can be deployed via a minimally invasive catheter.

EaglePicher Medical Power LLC, an EaglePicher company, is in the process of moving its headquarters to Plano, TX. The company supplies primary and rechargeable batteries for implantable medical devices. Previously located in Joplin, MO, the supplier plans to open its new facility in March 2009, complete with a state-of-the-art research and development center. The 20,000-sq-ft center will house laboratories and equipment for testing and manufacturing lithium batteries.

The Texas location was chosen to help the company better focus on the markets it serves and to provide room for growth. Having experienced an increase in growth and innovation in recent years as a result of demand for smaller, lighter-weight, more-advanced batteries, the company also plans to open a manufacturing plant at the Plano headquarters in the future. It currently operates two manufacturing facilities and one R&D center in Joplin.

The company’s batteries are suited for use in such medical devices as pacemakers, ICDs, heart monitors, pain-management devices, cochlear implants, and neuromodulation systems. It offers a range of electrochemistries for implantable applications, including lithium-ion, lithium manganese dioxide, lithium thionyl chloride, and lithium carbon monofluoride.

Scientists Develop Cancer-Killing Polymer Implant

Thursday, January 29th, 2009

Harvard University scientists have invented an implant that attracts and trains cells to kill cancer. An immunotherapeutic approach, the technique uses polymer material to induce the body’s immune system to recognize and destroy tumors.

Immunotherapy usually removes immune—or dendritic—cells from the body, exposes them to chemical activators and cancer-specific antigens, and then reintroduces them into the patient. However, most dendritic cells die when they reenter the body.

Confronting this problem, a team led by Harvard bioengineering professor David Mooney constructed a polymer that attracts dendritic cells by releasing a kind of chemical signal called a cytokine. The cells then enter spongelike holes in the polymer, where they become active. While attracting cancer-specific antigens to train the dendritic cells, the polymer is also covered with fragments of DNA whose sequences are typical of bacteria. When cells grab on to these fragments, they become highly activated, causing them to act as if they are in the midst of an infection. In cancer situations, tumors prevent the immune system from generating a strong response, but the simulation of infection provides the strong response required to kill tumors.

Mice with a deadly form of melanoma that have undergone Mooney’s experiment have achieved a survival rate of 90%. In contrast, conventional immunotherapies that require treating dendritic cells outside the body are only 60% effective.

If Mooney’s approach proves successful in humans, the polymer device may achieve faster FDA approval than cell therapies do, which face steep regulatory hurdles. The polymer material has been used safely in humans—for example, in biodegradable sutures. Predicting that safety tests involving large animals (the step before human trials) will progress quickly, Mooney expects to begin clinical trials of the cancer immunotherapy soon.

A more-detailed account of this immunotherapeutic approach is available at www.technologyreview.com/biomedicine/22027.

Contract Manufacturer Offers Regulatory Submission Program

Wednesday, January 28th, 2009
Contract manufacturer BC Tech, which specializes in Class I, II, and II devices, now offers a regulatory submission program.

Contract manufacturer BC Tech, which specializes in Class I, II, and II devices, now offers a regulatory submission program.

Product development and contract manufacturing services provider BC Tech (Santa Cruz, CA) has expanded on its current capabilities to offer a regulatory submission program. Designed to make the most of quality assurance measures already in place, the program runs parallel to the company’s development and manufacturing processes to anticipate regulatory milestones so that products can be properly submitted and then approved. This format is supposed to help reduce regulatory costs and time to market, according to the company. The program includes assistance with FDA 510(k) and PMA submissions, investigational device exemption applications, and relevant product safety certifications. In addition to risk analysis, the company offers documentation for design controls, prototyping, verification procedures, and manufacturing operations. Experienced in producing Class I, II, and III devices, the company employs manufacturing groups that specialize in mechanical engineering, industrial design, electronics, software, and bioresearch.

Nanoporous Metal Surfaces Could Improve Implants

Tuesday, January 27th, 2009

By chemically modifying the surfaces of such biocompatible metals as titanium, a multidisciplinary research team led by the Université de Montréal has produced metals with ‘intelligent’ surfaces that facilitate healing and acceptance of implants by the body. The altered surface’s ability to stimulate cell growth and development could eliminate the need for pharmaceuticals in future orthopedic, dental, and cardiovascular prostheses.

Upon applying chemical compounds to the biocompatible metal, the researchers exposed the materials to etching amalgams of acids and oxidants, which yielded a sponge-like pattern of nanopores in the surface. As a result, some cells adhered better to the modified surface than to traditional smooth ones, according to the research team. In addition, the team discovered that the surface promoted growth of bone cells, hampered growth of unwanted cells, and stimulated growth of stem cells better than untreated surfaces.

“An important element of this study is how we demonstrated the selective cellular effects of etching,” adds Antonio Nanci, a professor at the Université de Montréal’s Faculty of Dentistry. “With subtle changes in chemical composition of etching mixtures, we can alter the nanopatterns that are created on the metal surface and control consequent cellular responses.”

The study is detailed in the January 21 issue of Nano Letters.

Glucose Sensor: Coolest Tattoo Idea Yet

Monday, January 26th, 2009
A cell glows red after being injected with nanosensors that fluoresce in the presence of sodium. Credit: Heather Clark, Draper Laboratory

A cell glows red after being injected with nanosensors that fluoresce in the presence of sodium. Credit: Heather Clark, Draper Laboratory

Tattoos are all the rage these days. But scientists at Draper Laboratory (Cambridge, MA) are working toward the development of a different sort of “tattoo”—one that will monitor diabetics’ blood-sugar level.

Headed by Heather Clark, analytical chemist and task leader of Draper’s biomedical engineering group, a team of researchers is working to develop a biosensor that can be injected into the skin much like tattoo dye. Under infrared light, the device will fluoresce, informing diabetics whether or not they need to inject insulin following a meal. The monitoring technology will fall somewhere between noninvasive sensors for detecting glucose through the skin via infrared light and implanted devices for continually monitoring blood sugar and dispensing insulin.

The concept consists of 120-nm beads coated with a biocompatible material. Each bead contains a fluoroescent dye and sensor molecules that are designed to detect specific chemicals such as glucose and sodium. When injected into the skin, the sensor molecule pulls the target chemical into the polymer from the interstitial fluid that surrounds the cells. To compensate for the newly acquired positive charge of a sodium ion, for example, a dye molecule releases a positive ion, causing the molecule to fluoresce. The level of fluorescence increases with the concentration of the chemical target. Scientists can employ different recognition molecules to measure different targets, including chloride, calcium, and glucose.

The video below shows sodium rushing into heart-muscle cells grown in a dish. As happens during a normal heartbeat, sodium flowing into the heart coincides with contraction and modulates the sensors’ fluorescence (video by Heather Clark, Draper Laboratory).

The technology is unique, explains Clark, “because it doesn’t have any components to be used up.” Glucose strips, for example, detect glucose using an enzyme that must be replaced continually. “Other monitors, even nanosensors, have a limited lifetime, which makes implanting them difficult.”

The researchers have already conducted successful animal tests of a sodium-sensing version of the nanosensor that may eventually be used to monitor dehydration. When injected into the skin of mice, the polymer beads fluoresce in response to saline injections. While the glucose monitor has been shown to work in a solution, animal tests are still pending.

Although the technology looks promising, the researchers have much work ahead of them before the sensor is ready for human testing. While the beads didn’t appear to trigger an immune reaction in initial animal tests, notes Clark, more studies must be performed.

In the meantime, Clark projects that a future sensor may be injected into the surface layers of the skin, shallower than tattoo inks, “so that it sloughs off over time.” A fluorescence monitor resembling an optical mouse would then be used to measure the light emitted by the tattoo, and the sensor would be reinjected periodically.

Moog Acquires Ethox International

Friday, January 23rd, 2009

Moog Inc. (East Aurora, NY), a designer, manufacturer, and integrator of precision control components and systems, announced the acquisition of Ethox International (Buffalo, NY) today. Since 2006, Moog has steadily increased its presence in the medical device industry through a slew of acquisitions centering on various types of pumps. The acquisition of Ethox serves to further broaden Moog’s offerings to the medical device industry. Ethox specializes in the contract manufacture of medical disposables and provides microbiology, toxicology, and sterilization services.

Stretchable Electronics Twist and Strain

Friday, January 23rd, 2009
Optical image of a freely deformed stretchable array of complementary metal-oxide semiconductor inverters. Image Credit: John A. Rogers, University of Illinois at Urbana-Champaign.

Optical image of a freely deformed stretchable array of complementary metal-oxide semiconductor inverters. Image Credit: John A. Rogers, University of Illinois at Urbana-Champaign.

An intercollegiate research project has resulted in the development of materials and mechanical design strategies for flexible electronics suited for use in biomedical devices, among other applications. Because conventional wafer-based technologies can no longer satisfy some needs of developing devices, the researchers endeavored to explore electronic systems that could undergo extreme strain and bending without a reduction in electronic function.

Dubbing its design strategy noncoplanar mesh design, the team began by fabricating active circuits on silicon islands that form a chemically bonded prestrained elastomeric substrate. Upon releasing the prestrain, the circuits’ interconnects buckle and bend, creating arc-like formations that enable flexibility without compromising electrical properties. Single crystalline silicon nanomaterials served as the foundation of the design. Employment of these nanomaterials for the semiconductor demonstrated flexibility in CMOS integrated circuits close to that of similar devices that were formed on wafers.

The team, consisting of professors at the University of Miami College of Engineering, the University of Illinois, and Northwestern University, detailed their findings in the December issue of the Proceedings of the National Academy of Sciences.

Nonmagnetic Actuators Power Breakthrough Cancer Treatment Device

Friday, January 23rd, 2009

Nonmagnetic Nanomotion actuators supplied by Johnson Medtech (Shelton, CT) served as key components in the development of the world’s first MRI-compatible image-guided tumor treatment device. Manufactured by Profound Medical Inc. (Toronto), the minimally invasive thermal ablation device demonstrated in preclinical trials that it can treat prostate cancer as well as or better than radiation and may have fewer side effects.

Creating a major obstacle to success in this project in the past was the magnetic nature of electric motors and their components, which prohibited them from operating in an MRI environment. However, incorporation of the Nanomotion’s HR2-1-N-3 piezo ultrasonic nonmagnetic motors enabled the rotation of the device’s probe within the MRI environment.

“When designing our prostate cancer treatment device, we knew that it would require the visibility exclusively available in an MRI environment. However, conventional motors were a roadblock to creating a working proof-of-concept device and bringing this important development to reality,” says Michael Bronskill, chief technical officer of Profound Medical. “Johnson Medtech’s Nanomotion nonmagnetic motors provide the motion necessary to enable our tissue coagulation device to effectively treat prostate cancer patients within the MRI environment, and with a degree of precision that is crucial to success.”